Expert in Metabolic Dysfunction-associated Steatohepatitis
Explore our industry-leading
translational models of
NASH/MASH & HCC
Gubra’s flagship model GAN DIO-MASH is top-ranked by LITMUS consortium for its human proximity score and clinical translatability. Explore our model portfolio and latest findings to ensure a successful preclinical study.
Explore our data
Download the Latest Posters
Check out our posters and discover the clinical translatability of our flagship GAN DIO-MASH model, as well as other biopsy-confirmed preclinical models.
Standard Study Outlines
“
We are experts in bridging preclinical and clinical development.
MICHAEL FEIGH
Vice President, Scientific Sales
Michael’s primary focus is on MASH (NASH), MASH-HCC (NASH-HCC), IPF and IBD. Michael provides customers with scientific expertise in metabolic and fibrotic diseases, and knowhow for the preclinical evaluation of drug candidates from discovery to IND-enabling.
Let’s meet at the EASL 2023
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650